S
Saul Malozowski
Researcher at National Institutes of Health
Publications - 69
Citations - 5088
Saul Malozowski is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Diabetes mellitus & Randomized controlled trial. The author has an hindex of 27, co-authored 66 publications receiving 4789 citations. Previous affiliations of Saul Malozowski include University of New Mexico & Food and Drug Administration.
Papers
More filters
Journal ArticleDOI
Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
TL;DR: GH therapy offers benefits in body composition, exercise capacity, skeletal integrity, and quality of life measures and is most likely to benefit those patients who have more severe GHD, and the risks associated with GH treatment are low.
Journal ArticleDOI
Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH research society
Kenneth M. Attie,Bengt-Åke Bengtsson,Sandra L. Blethen,Werner F. Blum,Fergus J. Cameron,Jean Claude Carel,Lena M. S. Carlsson,John J. Chipman,Jens Sandahl Christiansen,Peter E. Clayton,David R. Clemmons,Pinchas Cohen,Stenvert L. S. Drop,Kenji Fujieda,Ezio Ghigo,Raymond L. Hintz,Ken K. Y. Ho,Mbelenge Mapoko Ilondo,Hector Jasper,Bernd Jesussek,Anne Marie Kappelgaard,Zvi Laron,Barbara Lippe,Saul Malozowski,Primus E. Mullis,Sabine M P F de MuinckKeizer-Schrama,Yoshikazu Nishi,John S. Parks,Charlotte Phelps,Michael B. Ranke,Iain C.A.F. Robinson,Ron G. Rosenfeld,Susan R. Rose,Paul Saenger,Guissepe Saggese,Martin O. Savage,Stephen M Shalet,Pierre C. Sizonenko,Christian J. Strasburger,Katsuhiko Tachibana,Toshiaki Tanaka,Michael O. Thorner,Kerstin Albertsson Wikland,Zvi Zadik +43 more
Journal ArticleDOI
Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
Journal ArticleDOI
Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial
Matthew C. Riddle,Walter T. Ambrosius,David J. Brillon,John B. Buse,Robert P. Byington,Robert M. Cohen,David C. Goff,Saul Malozowski,Karen L. Margolis,Jeffrey L. Probstfield,Adrian M. Schnall,Elizabeth R. Seaquist +11 more
TL;DR: These analyses implicate factors associated with persisting higher A1C levels, rather than low A 1C per se, as likely contributors to the increased mortality risk associated with the intensive glycemic treatment strategy in ACCORD.
Journal ArticleDOI
CLINICAL PRACTICE GUIDELINE Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
Mark E. Molitch,David R. Clemmons,Saul Malozowski,George R. Merriam,Stephen M Shalet,Mary Lee Vance +5 more
TL;DR: This research highlights the need to understand more fully the role of Epstein-Barr virus in the development of type 2 diabetes and its role in the immune system.